Home/Filings/4/A/0001516551-23-000069
4/A//SEC Filing

DHILLON PUNIT 4/A

Accession 0001516551-23-000069

CIK 0001516551other

Filed

Aug 30, 8:00 PM ET

Accepted

Aug 31, 11:26 AM ET

Size

13.1 KB

Accession

0001516551-23-000069

Insider Transaction Report

Form 4/AAmended
Period: 2023-08-25
DHILLON PUNIT
DirectorChief Executive Officer
Transactions
  • Purchase

    Common Stock

    2023-08-29$0.02/sh+881,000$16,47525,683,957 total
  • Small Acquisition

    Common Stock

    2023-08-28$0.02/sh+110,000$1,88124,802,957 total
  • Award

    Stock Option (Right to Buy)

    2023-08-25+2,253,0462,253,046 total
    Exercise: $0.01Exp: 2033-08-25Common Stock (2,253,046 underlying)
  • Award

    Common Stock

    2023-08-25+20,277,41424,683,957 total
  • Small Acquisition

    Common Stock

    2023-08-23$0.01/sh+9,000$10624,692,957 total
Holdings
  • Common Stock

    (indirect: By Trust)
    2,335,721
Footnotes (4)
  • [F1]Represents a restricted stock unit ("RSU") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $125M, an additional 25% vests upon achieving a market cap of $250M, an additional 25% vests upon achieving a market cap of $400M, an additional 25% vest at an exit of $500M or greater; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs . Notwithstanding anything to the foregoing, all of the RSUS shall vest if an exit greater than $500M is achieved at an earlier date.
  • [F2]Each RSU represents a contingent right to receive one share of the Issuer's common stock.
  • [F3]The shares are held by a trust for which the Reporting Person is a trustee and has voting and dispositive power over the shares.
  • [F4]The option grant shall be exercisable for a price of $0.014 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the four year period beginning August 24, 2023. Upon a change in control of the Issuer, 100% of the options will become fully vested.

Issuer

Skye Bioscience, Inc.

CIK 0001516551

Entity typeother

Related Parties

1
  • filerCIK 0001425052

Filing Metadata

Form type
4/A
Filed
Aug 30, 8:00 PM ET
Accepted
Aug 31, 11:26 AM ET
Size
13.1 KB